Ocular Therapeutix Inc. buy stratec
Start price
24.06.19
/
50%
€4.03
Target price
04.11.21
€21.00
Performance (%)
50.05%
End price
05.11.21
€6.05
Summary
This prediction ended on 05.11.21 with a price of €6.05. With a performance of 50.05% the BUY prediction by stratec was a big success. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Ocular Therapeutix Inc. | -28.935% | -28.935% | -27.391% | -69.453% |
| iShares Core DAX® | 1.051% | -1.833% | 12.822% | 15.392% |
| iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% | 42.396% |
| iShares Nikkei 225® | -1.778% | -8.115% | 16.092% | 0.891% |
| iShares S&P 500 | 0.002% | -2.226% | 28.387% | 41.095% |
Comments by stratec for this prediction
In the thread Ocular Therapeutix Inc. diskutieren
stratec stimmt dem Sentiment von 'Buy' zu
Over the weekend, JMP Securities reteirated their Buy rating and $9 price target on Ocular Therapeutix JMP's analyst noted 'the FDA approved Dextenza's sNDA for treating ocular inflammation following
ophthalmic surgery, roughly five months earlier than expected. He believes Dextenza will launch with both pain and inflammation indications and forecasts about $12 million of Dextenza sales in 2019, with a majority coming in the fourth quarter. Ocular has been "firing on all cylinders" since Dextenza was approved for both pain and inflammation and securing a C-code and a T-code'
Kursziel geändert auf 21,0
In the thread Trading Ocular Therapeutix Inc.
Die von stratec gewählte maximale Laufzeit wurde überschritten